ArticleFrontiers in oncology2026
Enhanced survival in resectable duodenal adenocarcinoma with adjuvant chemotherapy: evidence from a retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Duodenal adenocarcinoma (DA) is a rare malignancy, and the effectiveness of adjuvant chemotherapy on survival after surgical intervention remains ambiguous. This study investigates the impact of adjuvant chemotherapy on overall survival (OS) and recurrence-free survival (RFS) in patients with resectable DA. Materials and methods: Data from ninety-eight stage I-III DA patients who underwent surgical resection between January 1998 and December 2021 at two Chinese institutions were analyzed retrospectively. Survival outcomes were assessed using the Kaplan-Meier method, and multivariable Cox proportional hazards models identified significant prognostic factors. Results: Of the 98 patients, 45 received adjuvant chemotherapy and 53 did not. The median follow-up was 49 months. Patients who had adjuvant chemotherapy showed a longer median OS (52.9 vs. 25.1 months, p=0.003) and RFS (38.2 vs. 9.9 months, p<0.001) than those without. N stage was associated with reduced OS and RFS. Multivariate analysis identified adjuvant chemotherapy, N stage, and CA199 as independent predictors for RFS and OS. For patients with initial CA199 ≥ 27U/mL, adjuvant chemotherapy appeared to be associated with improvements in RFS and OS, alongside suggestive reductions in recurrence and mortality risks. Conclusion: Adjuvant chemotherapy correlates with an extended median OS and RFS, as well as a reduced risk of recurrence and mortality in patients who have undergone surgical resection for DA. Specifically, patients with DA who are in the N1 or N2 stage, or those with a CA199≥27U/mL at their initial diagnosis, may show potential clinical benefits from adjuvant chemotherapy as a preliminary exploratory finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.